The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status

Происхождение, передача и клиническая терапия коронавирусной болезни 2019 года (COVID-19): обновленная информация о текущем состоянии
De Yun Wang, Yan Yan, Kai Sen Tan, Yan-Rong Guo, Qing-Dong Cao, Zhong-Si Hong, Yuan-Yang Tan, Shou-Deng Chen, Hong-Jun Jin
2020-03-13

ACE2 receptorAntiviral therapiesCOVID-19Human-to-human transmissionSARS-CoV-2
An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.
1
As of 1 March 2020, WHO reported 87,137 confirmed cases and 2,977 deaths globally, corresponding to a 3.4% reported mortality proportion.
2
COVID-19 commonly presents with fever, cough, and fatigue; gastrointestinal symptoms occur in a smaller subset of patients.
3
Evidence demonstrated sustained human-to-human transmission and international exportation of COVID-19 cases.
4
Few specific antiviral therapies were available, while candidate antivirals and repurposed drugs were undergoing urgent investigation.
5
Older adults and people with underlying diseases are more susceptible to infection and severe outcomes, potentially involving ARDS and cytokine storm.
6
SARS-CoV-2 is a β-coronavirus with a genome highly similar to bat coronaviruses, identifying bats as the likely natural host.
7
SARS-CoV-2 uses the ACE2 receptor, as SARS-CoV does, and primarily spreads through the respiratory tract.

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in the human population

The epidemiology, origin and transmission, pathogenesis, clinical characteristics, and therapeutic strategies of COVID-19

Publication Details
Publication Date
2020-03-13
Journal
Publisher
ISSN
Cited by
4736
Access Type
Author Information
Authors
De Yun Wang
Yan Yan
Kai Sen Tan
Yan-Rong Guo
Qing-Dong Cao
Zhong-Si Hong
Yuan-Yang Tan
Shou-Deng Chen
Hong-Jun Jin
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%